Thanks, us. joining you Will. and morning, Good thank for everyone,
operate of has this both extremely first corporate begin which morning continues XXXX Bio-Path. with The of objectives. have our progress prexigebersen. clinical half with efficiently made I'm all an undeniably product for to lead we our I'll achieve team, our period strategy candidate, on productive cylinders proud and was the to executed and
Madrid. X we results. At interim were The results the acute for with with the of European to a we ASCO, our June, the showcased Meeting combination venetoclax AML. frontline of of oral and Chicago Clinical Association, of presentation recognized leukemia, both Annual At meetings in Society and in or we myeloid have In Oncology our medical an Hematology II the EHA decitabine meetings, from Phase study of therapy, field presence prexigebersen honored prestigious American treatment at most oncology. in Congress were in of or or ASCO
study our untreated with X and As refractory in II AML combination prexigebersen relapsed trial It AML. the of open-label is of X patients Phase previously study cohorts decitabine venetoclax an AML. you in is X-stage of Stage an in multi-center amended know, with and
resistant cohort will with The relapsed X-drug efficacy The achieve with of treatment complete venetoclax high-risk therapy refractory of current combination therapies. be or initial intolerant presented of includes X hematologic study who and are and of the administered for and for X at which relapsed incomplete data complete decitabine. signals recovery, number remission, remission and with interim the and X. third only refractory data who cohort the to but patients safely this and compelling the complete from interim patients hematologic includes These remission combination demonstrated diagnosed, ASCO primary endpoint Cohort considered chemotherapy, AML were recovery. better was EHA in Cohort newly AML partial patients prexigebersen showed that analysis efficacy than unsuitable not X cohort prexigebersen-based also standard The
are relapse new This a particularly patients oncologists these was encouraging It continued is treatment suboptimal. refractory in data population for understand need the a pleasure present world-leading patients an great options. audience challenging which to are and treat therapeutic AML who of current as options to
role common decade and of the thereby goal companion past announced become to respond The the likely molecular to probability treatment treatment. for the program. enhanced exciting to prexigebersen development more programs. accompany here also treatment, success biomarker During we oncology improving to this cancer The over more to of with many the patients second quarter, of emerging profile has genetic identify a development has a biomarkers is package a
advances. as We will keep project this cutting-edge you up-to-date
which targets program, BPXXXX BCLX. to now Turning
AML. and for correlated diagnosed with driving poor patients for is chronic untreated and BCL-X the know, has with the you Venetoclax of AML BHX XX% an to responsible CLL patients cell protein's expression neutralizing BCLX domain. improved up by of leukemia, has BCLX It antiapoptotic As survival is all protein shown patients. High prognosis works treatment for activity or against cancers. and been lymphocytic
transplantation, hematopoietic invariably with occurs treated allogeneic patients domain oftentimes disease relapse with due time. some exception the mutation of over However, cell to BHX
protein. BPXXXX also targets BCLX the
on not is the the BCLX based However, BPXXXX domain. and RNA messenger BHX blocking activity
believe a could BPXXXX an venetoclax As patients patients received have venetoclax treatments. for who including previously that result, who we provide relapsed, AML alternative
additional scheduled an quarter, of patients to including which During be standard of we toxicity, treat per require a clinical the relapsed AML, second -- for the with Phase ] treated patients would announced of monotherapy design. of escalation a venetoclax X cohort total patients. dosing second X+X dose Unless A tested. are dose relapsed in BPXXXX dose-limiting I/Ib our refractory portion completion the BPXXXX to resistant [ X is evalueable cohort there trial
of cohort there dose starting dose and dose-limiting first square is XX-milligram toxicities. consisted of meter a per no The
will the decitabine The efficacy Ib doses and of patients. with here. Phase you The approved total assess BPXXXX per refractory week, AML and combination X in after completion to a study relapsed for look administered of We forward treatment over portion over is weeks X doses commence of in of cohorts, X is progress expected our safety of to XX BPXXXX keeping days. monotherapy apprised cycle the
turn let's clinical I/Ib pancreatic triple-negative endometrial, solid Phase with in and ovarian, trial breast to our of Next, including BP-XXXX-A tumors, patients cancer.
is completion This with will to treat our readout have diagnosed is nanoparticle Patients poor patients. endometrial several look from leading and year. later in at may and is today's substance study and drug properties. to benefit from outcomes, ovarian potentially cancers this patients. provide safety cancer product it recurrent centers data sharing such that evaluate often challenging trial we clinical most to the initially this hope forward tumor cohort solid same We modified conducted being therapeutic prexigebersen BPXXXX-A the with a of the cancer enhanced with Some toolkit. and
and the STATX therapeutic malignancies STATX STATX also as that novel review pathway Finally, enhances and resistance. in a and breast in breast regulates taxol the work the processes breast, migration expression of Its and reduces made a we've cancers proliferation, targets and and ductal potential let's resistance antisense including colorectal is metastasis pancreatic cells line which with efficiently STATX oligodeoxynucleotide taxol aberrant ovarian BPXXXX, the in made promotes activation sensitivity drug It's STATX results displayed X-FU various cells role STATX the cancer progress characterize overexpression promotes These activity cancer which Activation BPXXXX cancer factor ovarian, transcription X-FU. previous antitumor tumorigenic in and that such colon target. with liposome-incorporated tumor in cancer are STATX and resistance. is liver many BPXXXX ovarian in numerous of tumor gemcitabine initiation lung, a enhanced plus cancer. adenocarcinoma. protein. cells.
will advanced submission novel us period extended patients have that application oligo therapy After with combination method the or testing, an to strategy to for to enable for Together, detection FDA. an for solid these testing, final IND safety tumors. results strongly we a finalize investigational drug, suggest BPXXXX of we complete plasma needed a is new and expect identified
We are limited particularly to validation options. first challenging of in excited indication therapy in-human that launch this has cutting-edge especially treatment our cancer an
the to With weeks highlights. financing. Anthony? call Anthony like from which to balance to brief financial clinical of to a of over financials that, underpinning Anthony review our over recent execute financial Price the I our $X plan. for This we've program sheet a sheet the I'll our review his development for our along now highlight in turn provides on with additional million quarter balance strengthened with funding Before turn that results, I'd
